PIP

PIP (Prolactin-Inducible Protein/GCDFP-15) is a secreted aspartyl proteinase that functions in extracellular matrix remodeling, cell adhesion, and receptor tyrosine kinase signaling. Synthesized in Golgi-derived vesicles and released by apical exocytosis from apocrine epithelial cells (PMID:6205595), PIP binds and cleaves fibronectin, binds actin, fibrinogen, CD4, and bacteria, with differential glycosylation modulating its binding preferences (PMID:7840903, PMID:12755619). PIP expression is stimulated by androgens via the androgen receptor and suppressed by estradiol, with Slug serving as an additional transcriptional activator in macrophages (PMID:2725533, PMID:10402478, PMID:31468711). In breast cancer cells, PIP supports serum-induced activation of AKT, ERK1/2, and JNK1 downstream of focal adhesion kinase and EphB3 signaling, and in salivary gland acinar cells it directly interacts with aquaporin AQP5 to regulate its apical membrane localization (PMID:23755096, PMID:34440877).

1. 1984 Medium

   Establishing that PIP is a secretory protein released via a defined exocytic pathway resolved how this glycoprotein reaches the extracellular space in apocrine tissues.

   Evidence Colloidal gold immunoelectron microscopy of apocrine epithelium localizing GCDFP-15 to Golgi vesicles and cytoplasmic granules with apical release

   PMID:6205595

   Open questions at the time

   • Signals directing PIP to the secretory pathway not identified
   • Whether other cell types use the same exocytic route was not tested
2. 1989 Medium

   Demonstrating that estradiol suppresses and DHT stimulates PIP mRNA and protein secretion established steroid hormone control of PIP expression and framed PIP as an androgen-responsive gene in breast cancer.

   Evidence Northern blot and secretion assays in ZR-75-1 breast cancer cells with estradiol, DHT, dexamethasone, and antiestrogen treatments

   PMID:2725533

   Open questions at the time

   • Cis-regulatory elements mediating hormonal control not mapped
   • Whether AR directly binds the PIP promoter was not shown
3. 1994 Medium

   Identifying actin, fibrinogen, and bacteria as PIP-binding partners, and attributing molecular mass heterogeneity to carbohydrate modifications, expanded PIP from a secretory marker to a multifunctional extracellular effector.

   Evidence Binding assays with immobilized proteins, electron microscopy localization to bacterial cell walls, biochemical deglycosylation

   PMID:7840903

   Open questions at the time

   • Functional consequences of actin and fibrinogen binding not tested
   • Binding affinities not quantified
4. 1999 Medium

   Confirming that AR mediates DHT-induced PIP expression using pure antiandrogens in multiple cell lines consolidated the androgen receptor as a direct transcriptional regulator of PIP.

   Evidence mRNA and secretion assays in MFM-223 and ZR-75-1 cells with DHT, hydroxyflutamide, and casodex

   PMID:10402478

   Open questions at the time

   • Direct AR occupancy of PIP regulatory regions not demonstrated by ChIP
   • Contribution of AR co-regulators unknown
5. 2003 High

   Identifying PIP as an aspartyl proteinase that cleaves fibronectin, and mapping its fibronectin-binding domain and differential glycosylation between pathological and physiological forms, established the enzymatic activity and substrate specificity of PIP.

   Evidence RP-HPLC, SELDI-TOF, QStar MS/MS mass spectrometry, enzymatic digestion assays, protein-protein interaction mapping

   PMID:12755619

   Open questions at the time

   • Catalytic residues not mutagenized to confirm aspartyl protease mechanism
   • Other potential substrates not surveyed systematically
6. 2013 Medium

   Showing that PIP depletion abolishes serum-induced AKT, ERK1/2, and JNK1 activation and reduces FAK and EphB3 phosphorylation placed PIP upstream of major RTK-dependent proliferative and adhesion signaling cascades in breast cancer cells.

   Evidence siRNA knockdown in T47D cells with RTK phosphorylation arrays, western blot, fibronectin adhesion and stress fiber assays

   PMID:23755096

   Open questions at the time

   • Whether PIP acts via its protease activity or as a ligand/scaffold to promote RTK signaling is unresolved
   • Rescue with wild-type and protease-dead PIP not performed
   • Generalizability beyond T47D cells not tested
7. 2019 Medium

   Identifying Slug as a transcriptional activator of PIP in macrophages, with secreted PIP driving pulmonary arterial smooth muscle cell proliferation, extended PIP's function beyond breast tissue into pulmonary vascular disease.

   Evidence Immunohistochemistry, rat model of pulmonary fibrosis-associated pulmonary hypertension, Slug inhibition reducing PH severity, smooth muscle cell proliferation assay

   PMID:31468711

   Open questions at the time

   • Direct Slug binding to PIP promoter not shown
   • Receptor or mechanism by which extracellular PIP drives smooth muscle cell proliferation not identified
8. 2021 High

   Demonstrating a direct PIP–AQP5 interaction with defined stoichiometry and showing that PIP loss disrupts AQP5 apical localization in salivary glands revealed PIP as a regulator of aquaporin trafficking with implications for Sjögren's syndrome.

   Evidence Co-immunoprecipitation, in vitro binding with domain mapping, PIP knockout mouse model, immunofluorescence in human and mouse salivary gland tissue

   PMID:34440877

   Open questions at the time

   • Mechanism by which PIP maintains AQP5 at the apical membrane (retention vs. trafficking) not dissected
   • Whether this interaction is relevant in other AQP5-expressing tissues is unknown

• It remains unknown whether PIP's protease activity versus its scaffolding/binding properties drive its effects on RTK signaling and cell adhesion, and the catalytic mechanism has not been validated by active-site mutagenesis.
• No structure–function separation of protease versus binding activities
• No crystal structure or active-site mutagenesis
• Physiological substrates beyond fibronectin not systematically identified